Home/Pipeline/CS1

CS1

Pulmonary Arterial Hypertension (PAH)

Phase IIActive; Phase IIa completed, Phase IIb in preparation

Key Facts

Indication

Pulmonary Arterial Hypertension (PAH)

Phase

Phase II

Status

Active; Phase IIa completed, Phase IIb in preparation

Company

Cereno Scientific

About Cereno Scientific

Cereno Scientific is a clinical-stage biotech focused on developing first-in-class, disease-modifying treatments for rare cardiovascular and pulmonary diseases with high unmet need. The company's strategy leverages orphan drug designations and accelerated pathways to efficiently advance its dual-platform pipeline, led by Phase II candidate CS1 for Pulmonary Arterial Hypertension (PAH). With a Phase II asset, a Phase I candidate, and a preclinical program, Cereno is positioned for value inflection through clinical milestones and potential partnerships.

View full company profile

Therapeutic Areas

Cardiovascular Pulmonary

Other Pulmonary Arterial Hypertension (PAH) Drugs

Drug	Company	Phase	Status
YUTREPIA™ (treprostinil) inhalation powder	Liquidia	Approved	Commercial
LIQ861 (treprostinil) inhalation powder	Liquidia	Phase 3	Completed
L606 (liposomal treprostinil) injection	Liquidia	Preclinical	Active
NTP42	ATXA Therapeutics	Phase 1	Active; Orphan Drug Designation from FDA and EMA. Phase 1 results published.
Transdermal Treprostinil Prodrug Patch	Corsair Pharma	Pre-clinical	Active
Anti-EMAP II monoclonal antibody	Allinaire Therapeutics	Pre-clinical	Active
Tiprelestat	tiakis Biotech	Phase 2	Active
Seralutinib	Chiesi	Phase 3	Active
Sotatercept	Merck	Phase 3	Active
TPIP (Treprostinil Palmitil Inhalation Powder)	Insmed	Phase 2b	Active
Ralinepag	United Therapeutics	Phase 3	Active (ADVANCE CAP)
Beraprost MR	United Therapeutics	Phase 3	Active (ISABELA)